1. Home
  2. TAVI vs DERM Comparison

TAVI vs DERM Comparison

Compare TAVI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TAVI
  • DERM
  • Stock Information
  • Founded
  • TAVI 2024
  • DERM 2014
  • Country
  • TAVI United States
  • DERM United States
  • Employees
  • TAVI N/A
  • DERM N/A
  • Industry
  • TAVI
  • DERM Biotechnology: Pharmaceutical Preparations
  • Sector
  • TAVI
  • DERM Health Care
  • Exchange
  • TAVI Nasdaq
  • DERM Nasdaq
  • Market Cap
  • TAVI 163.0M
  • DERM 181.0M
  • IPO Year
  • TAVI 2024
  • DERM 2021
  • Fundamental
  • Price
  • TAVI $10.18
  • DERM $6.28
  • Analyst Decision
  • TAVI
  • DERM Strong Buy
  • Analyst Count
  • TAVI 0
  • DERM 2
  • Target Price
  • TAVI N/A
  • DERM $10.00
  • AVG Volume (30 Days)
  • TAVI 4.1K
  • DERM 104.8K
  • Earning Date
  • TAVI 01-01-0001
  • DERM 08-11-2025
  • Dividend Yield
  • TAVI N/A
  • DERM N/A
  • EPS Growth
  • TAVI N/A
  • DERM N/A
  • EPS
  • TAVI 0.12
  • DERM N/A
  • Revenue
  • TAVI N/A
  • DERM $56,243,000.00
  • Revenue This Year
  • TAVI N/A
  • DERM $28.99
  • Revenue Next Year
  • TAVI N/A
  • DERM $52.61
  • P/E Ratio
  • TAVI $82.70
  • DERM N/A
  • Revenue Growth
  • TAVI N/A
  • DERM N/A
  • 52 Week Low
  • TAVI $9.89
  • DERM $3.54
  • 52 Week High
  • TAVI $10.72
  • DERM $8.25
  • Technical
  • Relative Strength Index (RSI)
  • TAVI N/A
  • DERM 38.72
  • Support Level
  • TAVI N/A
  • DERM $6.29
  • Resistance Level
  • TAVI N/A
  • DERM $7.13
  • Average True Range (ATR)
  • TAVI 0.00
  • DERM 0.41
  • MACD
  • TAVI 0.00
  • DERM -0.15
  • Stochastic Oscillator
  • TAVI 0.00
  • DERM 3.31

About TAVI Tavia Acquisition Corp. Ordinary Shares

Tavia Acquisition Corp is a blank check company.

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Share on Social Networks: